1-(6-chloro-4-methylquinazolin-2-yl)guanidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-(6-chloro-4-methylquinazolin-2-yl)guanidine
• 英文别名: 2-Guanidino-4-methyl-6-chlorchinazolin；2-Guanidino-6-chlor-4-methyl-chinazolin；(6-chloro-4-methyl-quinazolin-2-yl)-guanidine；(6-Chlor-4-methyl-chinazolin-2-yl)-guanidin；N-(6-chloro-4-methyl-2-quinazolinyl)guanidine；2-(6-chloro-4-methylquinazolin-2-yl)guanidine
• 化学式: C₁₀H₁₀ClN₅
• 分子量: 235.676
• InChiKey: ROVKPIHVVRWXAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  90.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(6-chloro-4-methylquinazolin-2-yl)guanidine 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 、 ((3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)oxy)tri(pyrrolidin-1-yl)phosphonium hexafluorophosphate(V) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 N2-(6-chloro-4-methylquinazolin-2-yl)-N4-(3-(dimethylamino)propyl)-6-methylpyrimidine-2,4-diamine
  参考文献：
  名称：

  探索配体和 G4 DNA 之间芳烃-芳烃相互作用中的色散和静电成分以开发 G4-配体

  摘要：

  G-四链体 (G4) DNA 结构是中央生物过程中的重要调控元件。选择性结合并稳定G4结构的小分子具有治疗潜力，目前已知的G4配体有>1000。尽管如此，只有两种 G4 配体进入了临床试验。在这项工作中，我们合成了几种杂环G4配体，并使用生化测定研究了它们与G4（例如来自c-MYC 、 c-KIT和BCL-2启动子的G4）的相互作用。我们进一步研究了所选化合物对细胞活力的影响、对细胞中 G4 数量的影响及其药代动力学特性。这确定了具有合适特性的有效 G4 配体，并进一步揭示了芳烃-芳烃相互作用中的分散成分与缺电子静电相结合，对于配体与 G4 有效结合至关重要。所提出的设计策略可应用于进一步开发具有合适特性的 G4 配体，以探索 G4 作为治疗靶点。

  DOI：

  10.1021/acs.jmedchem.3c02127
• 作为产物：
  描述：

  对氯苯胺 在 盐酸 、 碘 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 0.17h， 生成 1-(6-chloro-4-methylquinazolin-2-yl)guanidine
  参考文献：
  名称：

  Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure

  摘要：

  The heme enzyme myeloperoxidase (MPO) participates in innate immune defense mechanism through formation of microbicidal reactive oxidants. However, evidence has emerged that MPO-derived oxidants contribute to propagation of inflammatory diseases. Because of the deleterious effects of circulating MPO, there is a great interest in the development of new efficient and specific inhibitors. Here, we have performed a novel virtual screening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtual screening. Starting from a set of 727842 compounds, 28 molecules were selected by this virtual method and tested on MPO in vitro. Twelve out of 28 compounds were found to have an IC50 less than 5 mu M. The best inhibitors were 2-(7-methoxy-4-methylquinazolin-2-yl)guanidine (28) and (R)-2-(14(2,3-dihydro-1H-imidazol-2-yl-methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo[d]imidazole (42) with IC50 values of 44 and 50 nM, respectively. Studies on the mechanism of inhibition suggest that 28 is the first potent mechanism-based inhibitor and inhibits irreversibly MPO at nanomolar concentration.

  DOI：

  10.1021/acs.jmedchem.7b00285

文献信息

• Compounds for the treatment of pain
  申请人：——

  公开号：US20030176314A1

  公开（公告）日：2003-09-18

  This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.

  这项发明提供了治疗疼痛、尿失禁和其他由NPFF受体介导的异常的方法，包括向受试者施用在NPFF1受体、NPFF2受体或同时在NPFF1和NPFF2受体上起作用的化学化合物的治疗有效量。
• Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
  申请人：——

  公开号：US20030139431A1

  公开（公告）日：2003-07-24

  This invention provides compounds having the structure: 1 wherein X=CH, C(CH 3 ) or N; each of R 1 , R 2 , R 3 , R 4 and R 5 is independently H, C 1 -C 10 straight chained or branched alkyl, C 2 -C 10 straight chained or branched alkenyl, C 2 -C 10 straight chained or branched alkynyl, C 3 -C 10 cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, —CN, —C(═Z)R 6 , —C(═Z)OR 6 , —C(═Z)N(R 6 ) 2 , —N(R 6 )—C(═Z)R 6 , —N(R 6 )—C(═Z)N(R 6 ) 2 , —OC(═Z)R 6 , —C(═Z)OR 6 —OR 6 or —SR 6 ; wherein Z is O or S; and wherein R 6 is C 1 -C 10 straight chained or branched alkyl, aryl, (CH 2 ) n Q, C 2 -C 10 alkenyl, C 3 -C 10 cycloalkyl, C 5 -C 10 cycloalkenyl, wherein Q is OR 7 , SR 7 , N(R 7 ) 2 or aryl, wherein R 7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, wherein R 2 and R 3 and the carbons to which they are attached form a fused aryl, heteroaryl, C 5 -C 10 cyclic alkyl or heterocyclic alkyl ring; or wherein R 3 and R 4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R a , where R a is 1) hydroxy, 2) C 1 -C 10 alkoxy, 3) halogen, 4) nitro, 5) amino, 6) CF 3 , or 7) carboxy, and each cycloalkyl group is optionally substituted with a substituent independently selected from R b , where R b is 1) a group selected from R a , 2) C 1 -C 7 alkyl, 3) C 2 -C 7 alkenyl, 4) C 2 -C 7 alkynyl or 5) cyclic C 1 -C 10 alkyl, and each aryl is optionally substituted with R 1 . This invention also provides methods of treating pain, urge incontinence; as well as methods of preparing the compounds.

  这项发明提供了具有以下结构的化合物：其中 X==CH，C(CH3)或N；R1、R2、R3、R4和R5中的每一个独立地是H、C1-C10直链或支链烷基、C2-C10直链或支链烯基、C2-C10直链或支链炔基、C3-C10环烷基、取代或未取代芳基、羟基、卤代醚、硝基、氨基、卤素、—CN、—C(═Z)R6、—C(═Z)OR6、—C(═Z)N(R6)2、—N(R6)—C(═Z)R6、—N(R6)—C(═Z)N(R6)2、—OC(═Z)R6、—C(═Z)OR6—OR6或—SR6；其中 Z 是 O 或 S；且其中 R6 是 C1-C10直链或支链烷基、芳基、(CH2)nQ、C2-C10烯基、C3-C10环烷基、C5-C10环烯基，其中 Q 是OR7、SR7、N(R7)2或芳基，其中 R7 是H、烷基、烯基、炔基、环烷基、环烯基、芳基，其中 R2、R3和它们连接的碳形成融合芳基、杂芳基、C5-C10环烷基或杂环烷基环；或其中 R3、R4和它们连接的碳形成融合芳基、杂芳基、环烷基或杂环烷基环；以及每个烷基、烯基、炔基和烷氧基组分可以选择性地取代一个从 Ra 中独立选择的取代基，其中 Ra 是 1) 羟基，2) C1-C10烷氧基，3) 卤素，4) 硝基，5) 氨基，6) CF3，或 7) 羧基，每个环烷基组分可以选择性地取代一个从 Rb 中独立选择的取代基，其中 Rb 是 1) 从 Ra 中选择的一组，2) C1-C7烷基，3) C2-C7烯基，4) C2-C7炔基或 5) 环状 C1-C10 烷基，每个芳基可以选择性地取代为 R1。这项发明还提供了治疗疼痛、尿急失禁的方法；以及制备这些化合物的方法。
• Condensation reactions of guanidines with bis-electrophiles: formation of highly nitrogenous heterocycles
  作者：David M. Arnold、Matthew G. LaPorte、Shelby M. Anderson、Peter Wipf

  DOI：10.1016/j.tet.2013.04.127

  日期：2013.9

  2-Amino-1,4-dihydropyrimidines were reacted with bis-electrophiles to produce novel fused bipyrimidine, pyrimidoaminotriazine, and pyrimidosulfonamide scaffolds. In addition, a quinazoline library was constructed using a guanidine Atwal-Biginelli reaction with 1-(quinazolin-2-yl)guanidines. The product heterocycles have novel constitutions with high nitrogen atom counts and represent valuable additions to screening libraries for the discovery of new modulators of biological targets. (C) 2013 Elsevier Ltd. All rights reserved.
• [EN] COMPOUNDS FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：SYNAPTIC PHARMA CORP

  公开号：WO2003026657A1

  公开（公告）日：2003-04-03

  This invention provides methods of treating pain, urinary incontinence and other abnormalities mediated by a NPFF receptor, which comprises administering to a subject a therapeutically effective amount of a chemical compound which acts at the NPFF1 receptor, the NPFF2 receptor, or at both the NPFF1 and NPFF2 receptors.
• Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure
  作者：Jalal Soubhye、Ibaa Chikh Alard、Iyas Aldib、Martine Prévost、Michel Gelbcke、Annelise De Carvalho、Paul G. Furtmüller、Christian Obinger、Jörg Flemmig、Sara Tadrent、Franck Meyer、Alexandre Rousseau、Jean Nève、Véronique Mathieu、Karim Zouaoui Boudjeltia、François Dufrasne、Pierre Van Antwerpen

  DOI：10.1021/acs.jmedchem.7b00285

  日期：2017.8.10

  The heme enzyme myeloperoxidase (MPO) participates in innate immune defense mechanism through formation of microbicidal reactive oxidants. However, evidence has emerged that MPO-derived oxidants contribute to propagation of inflammatory diseases. Because of the deleterious effects of circulating MPO, there is a great interest in the development of new efficient and specific inhibitors. Here, we have performed a novel virtual screening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtual screening. Starting from a set of 727842 compounds, 28 molecules were selected by this virtual method and tested on MPO in vitro. Twelve out of 28 compounds were found to have an IC50 less than 5 mu M. The best inhibitors were 2-(7-methoxy-4-methylquinazolin-2-yl)guanidine (28) and (R)-2-(14(2,3-dihydro-1H-imidazol-2-yl-methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo[d]imidazole (42) with IC50 values of 44 and 50 nM, respectively. Studies on the mechanism of inhibition suggest that 28 is the first potent mechanism-based inhibitor and inhibits irreversibly MPO at nanomolar concentration.